Primary Sclerosing Cholangitis (PSC) research hub
5 indexed studies · 1 currently recruiting
- ongoing, recruitingTherapeutic exploratory (Phase II)
An Open Label, Phase 2 Study to Evaluate the Effect of A3907 on Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Adults with Primary Sclerosing Cholangitis (PSC)
This study is testing a new medicine, A3907, for people with Primary Sclerosing Cholangitis (PSC). Researchers want to see how safe it is and if people can take it without too many problems over 12 weeks.
Spain · Italy · France - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Mass Balance Study of [14C]-IPN60250 in Healthy Adult Participants
This study is testing a new medicine called IPN60250 in healthy men to see how it moves through the body. It helps us understand what happens to the medicine after it's taken, which is important for future use in conditions like primary sclerosing cholangitis (PSC).
Netherlands - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A study to characterize the pharmacokinetic profile of norucholic acid (NCA) in patients with primary sclerosing cholangitis (PSC)
This study is looking at how a new medicine, called norucholic acid (NCA), moves through the bodies of people with primary sclerosing cholangitis (PSC). It's an early stage study to understand the medicine better.
Germany · Austria · Finland - recruitingNA
Biodegradable Stents in Primary Sclerosing Cholangitis
This study is looking into a new type of dissolvable tube (biodegradable stent) for people with Primary Sclerosing Cholangitis (PSC). It aims to see if these stents can help unblock bile ducts better than current treatments and reduce the number of procedures needed.
United Kingdom - ongoing, recruitingTherapeutic confirmatory (Phase III)
Double-blind, randomized, placebo-controlled, phase III study comparing norursodeoxycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis
This study is looking into a new medication called NUC01 for a liver condition called primary sclerosing cholangitis (PSC). It compares NUC01 with a dummy medicine (placebo) to see if it can improve liver health and stop the condition from getting worse.
Denmark · Austria · Norway